EMRELIS 100 mg/mL
Telisotuzumab Vedotin · INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · AbbVie Inc.
EMRELIS is a injection, powder, lyophilized, for solution containing telisotuzumab vedotin at 100 mg/mL, taken intravenous. Manufactured by AbbVie Inc..
Key Facts
- Brand Name
- EMRELIS
- Generic Name
- Telisotuzumab Vedotin
- NDC Code (Product)
0074-1055- Manufacturer
- AbbVie Inc.
- Strength
- 100 mg/mL
- Dosage Form
- INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
- Route
- INTRAVENOUS
- Marketing Status
- Application #
- BLA761384
- Marketing Start
- 05/14/2025
Recall History
No Recall HistoryFrequently Asked Questions
What is EMRELIS used for?
EMRELIS contains Telisotuzumab Vedotin. It is a injection, powder, lyophilized, for solution taken intravenous. Consult your doctor for specific uses.
Is EMRELIS a controlled substance?
EMRELIS is not classified as a controlled substance by the DEA.
What is the generic name for EMRELIS?
The generic name for EMRELIS is Telisotuzumab Vedotin. There are no other listed brand versions of Telisotuzumab Vedotin.
What is the NDC code for EMRELIS 100 mg/mL?
The NDC (National Drug Code) for EMRELIS 100 mg/mL is 0074-1055, listed by AbbVie Inc..
Other EMRELIS Dosages
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)